Company Search:
Advanced Search
Sponsored Links
Hypera SA Company Snapshot
Hypera SA operates in the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Hypera SA with three other pharmaceutical manufacturers in Latin America: Fleury SA (2019 sales of 2.91 billion Brazilian Reals [US$549.99 million] of which 84% was Diagnostic Medicine), Diagnosticos Da America SA (4.36 billion Brazilian Reals [US$826.30 million] of which 100% was servi os auxiliares), and Genomma Lab Internacional Sab De Cv which is based in MEXICO (12.71 billion Mexican Pesos [US$639.97 million] of which 100% was PC).

Sales Analysis. Hypera SA reported sales of 3.29 billion Brazilian Reals (US$623.76 million) for the year ending December of 2019. This represents a decrease of 11.5% versus 2018, when the company's sales were 3.72 billion Brazilian Reals.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Hypera SA
  Stock Performance Chart for Hypera SA
  Stock Data: Recent Stock Performance:
  Current Price (1/15/2021): 34.80
(Figures in Brazilian Reals)
1 Week -1.4%   13 Weeks 2.7%  
4 Weeks 14.3%   52 Weeks -7.0%  
Hypera SA Key Data:
  Ticker: HYPE3 Country: Brazil
  Exchanges: SOP Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2019 Sales 3,294,749,000
(Year Ending Jan 2020).
Employees: 7,515
  Currency: Brazilian Reals Market Cap: 22,039,220,956
  Fiscal Yr Ends: December Shares Outstanding: 633,310,947
  Share Type: Ordinary Closely Held Shares: 268,697,602
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.